Novel Combo Assay for Early Detection of Drug Induced Liver Injury (DILI)”, in short “Combo LiverAce”
The overall objective of the ”LiverAce” project is to develop, demonstrate and validate a new innovative Assay for the assessment of Drug Induce Liver Injury (DILI). Combo LiverAce, will be the first ‘assay’ developed that combines miRNA and protein biomarkers detection for diagnosing DILI in a single step assay. By combining the detection of an specific panel of miRNA and proteins of predictive value in DILI, Combo LiverAce has the capacity to transform diagnosis in this area of clinical diagnostics.
Co-founded by EUREKA member countries and the European Union Horizon 2020 Framework Programme.
This project has been founded under the project code E! 114589 - LiverAce.